TiGenix NV, a pioneering biotechnology company headquartered in Belgium, focuses on developing innovative cell-based therapies for severe medical conditions. Founded in 2007, TiGenix has made significant strides in the regenerative medicine sector, particularly in the treatment of inflammatory and degenerative diseases. The company is renowned for its flagship product, ChondroCelect, which is the first cell-based therapy approved in Europe for the repair of cartilage defects in the knee. TiGenix's commitment to advancing cell therapy positions it as a leader in the industry, with a strong emphasis on research and development. With a robust pipeline and strategic partnerships, TiGenix continues to enhance its market presence, aiming to transform patient care through cutting-edge therapeutic solutions.
We don't have data for TiGenix NV, but we can show you information about their parent organization instead.
View parent company